Bpifrance

Ecoat develops bio-based chemistries tailored for the coatings industry, focusing on sustainable solutions. The company offers a range of water-based, bio-based products, including bio-based alkyd emulsions, acrylics, and specialty oils. Its product lineup features innovative offerings such as secoia, inokem, air purifying emulsions, and solkem, all designed to promote environmental sustainability within the paint and coating sector. By emphasizing the adoption of eco-friendly materials, Ecoat aims to facilitate the industry's transition towards more sustainable practices.

Orakl Oncology is dedicated to accelerating drug discovery in oncology using advanced biology and AI-powered analysis. The company utilizes a distinct collection of patient tumor avatars that integrates both biological and clinical data to enhance cancer treatment options.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

Afyren is a sustainable chemistry company focused on developing innovative biotechnological solutions that valorize non-food biomass while promoting environmental sustainability. The company aims to replace petroleum-based ingredients with bio-sourced products, aligning its operations with a circular and low-carbon economy. Utilizing natural microorganisms, Afyren produces a range of seven organic acids derived entirely from renewable sources, along with a high-value-added fertilizer. Through its efforts, Afyren contributes to the transformation of the chemical industry by providing eco-friendly alternatives that reduce reliance on fossil fuels.

Faircraft is focused on creating a sustainable alternative to animal leather by utilizing advanced synthetic biology and material science techniques. The company develops a lab-grown product through cellular culture and tissue engineering, providing a slaughter-free option that meets the needs of the fashion industry. This innovative approach aims to reduce CO2 emissions while delivering a material that boasts high mechanical strength and durability. Faircraft's commitment to sustainability positions it as a leader in the movement toward more environmentally friendly fashion solutions.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Enalees develops molecular diagnostic tests for pets that can be used directly by veterinarians.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Injectpower creates energy storage technologies and micro-batteries for medical implants. Its small solid-state battery allows devices to function as sensors or actuators, collecting data continuously and autonomously for weeks without needing to be recharged. Their micro-batteries, which have been developed over 16 years and have 40 patents, are manufactured utilizing a verified semiconductor supply chain and have high reliability.

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates an industrial pilot, is completing the construction of its demo plant in Germany, and is preparing its first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE).

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates an industrial pilot, is completing the construction of its demo plant in Germany, and is preparing its first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE).

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.

Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Ynsect is a biotech company based in Evry, France, specializing in the production and processing of insects for use in animal feed and non-food applications. Founded in 2011, the company operates insect production facilities that utilize bioconversion processes to transform organic resources into high-quality nutrients, including proteins and lipids for livestock and pet nutrition, as well as organic fertilizers and bioenergy. Ynsect's innovative approach allows for large-scale insect farming and automation, making it a preferred partner for agri-food professionals, laboratories, and investors. Through its expertise, Ynsect aims to provide sustainable and premium nutrition solutions, addressing the growing demand for alternative protein sources in the agro-food and environmental biotech sectors.

Odimma is a biotech company that focuses on precision medicine and cure for personalized cancer immunotherapy.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Ecoat develops bio-based chemistries tailored for the coatings industry, focusing on sustainable solutions. The company offers a range of water-based, bio-based products, including bio-based alkyd emulsions, acrylics, and specialty oils. Its product lineup features innovative offerings such as secoia, inokem, air purifying emulsions, and solkem, all designed to promote environmental sustainability within the paint and coating sector. By emphasizing the adoption of eco-friendly materials, Ecoat aims to facilitate the industry's transition towards more sustainable practices.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Mycophyto, co-founded in July 2016 by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise, specializes in biological crop protection based on three decades of research. The company develops customized products and offers specific support services to facilitate innovative agricultural systems. Mycophyto's plant production system focuses on identifying indigenous fungi and beneficial soil pathogens that enhance plant growth. By cultivating these microorganisms in an integrated greenhouse, the company enables researchers to grow a variety of plants, crops, and herbs sustainably, reducing dependence on chemical fertilizers. Through its unique approach, Mycophyto aims to advance agricultural practices while promoting environmental sustainability.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

BioMAdvanced Diagnostics is a developer of molecular diagnostic and biomarker tests. These tests are intended to be integrated into conventional diagnostic and treatment protocols, to be simple to use for personnel caring for specific patients, and to be highly affordable. Its goal is to provide truly individualized care, which would dramatically enhance patient outcomes by giving physicians unparalleled tools.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.

Apmonia Therapeutics developing a pipeline of next generation peptide based therapies targeting the tumor microenvironment to improve the lives of patients with cancer. If anyone would want to contact them please contact them via phone call or email.

Carroucell is the microcarrier supplier for cell culture in bioreactor.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Øzers is a French foodtech company that specializes in creating innovative sports nutrition products using only healthy, vegan ingredients. Founded by a professional boxer and an engineer, the company collaborates with biotech engineers and medical professionals to develop its offerings. Øzers focuses on enhancing athletic performance without compromising health, providing ultra-functional edible supplements made from plant-based ingredients, including vegetable proteins, microalgae, vitamins, and minerals. By utilizing the potential of these natural components, Øzers aims to support athletes in achieving their maximum performance.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in the resolution of inflammation, utilizing monoclonal antibodies to address these conditions. By inhibiting specific targets implicated in early inflammatory processes and the recruitment of innate immune cells, Thabor Therapeutics aims to provide effective therapies that enable healthcare providers to improve patient outcomes.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Vaxxel is an Innovative viral live-attenuated platform that develops novel and proprietary live-attenuated vaccine candidates against bronchiolitis and pneumonia caused by pneumovirus.

Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.

SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.

CarbonWorks is specialising in the use of microalgae to capture and utilise carbon dioxide.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Cureety is a telemedicine startup focused on enhancing the follow-up and care of cancer patients through its healthcare telemonitoring platform. The platform provides tools that support healthcare professionals in adjusting cancer treatments and collecting real-world data. This data collection not only aids in better patient care but also contributes to research initiatives, allowing researchers and industry stakeholders to advance their understanding and treatment of cancer. By transforming the care pathway for cancer patients, Cureety aims to improve overall patient outcomes and foster ongoing research programs in the field.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Depixus is a biotechnology company that has developed a novel technology designed for real-time analysis of individual biomolecular interactions at a large scale. Its platform enables comprehensive genome analysis, allowing researchers to examine entire genomic regions quickly and efficiently. This integrated system provides the flexibility to specify the desired level of sequence and epigenetic detail, facilitating the discovery of new biological pathways and the decoding of disease mechanisms. By enhancing the understanding of these processes, Depixus aims to contribute to the development of new precision medicines. The company's focus on advanced DNA and RNA sequencing technologies addresses the limitations of current methods, particularly in achieving single-molecule precision.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

SPARTHA Medical is a medical technology company focused on developing innovative coatings that enhance the safety of medical devices and consumer products by protecting against microbial and inflammatory risks. The company utilizes natural biopolymers to create invisible, eco-friendly, and biocompatible coatings that possess antibacterial, antiviral, and anti-inflammatory properties. By employing a patented technology that allows for the precise control of the assembly of two different polyelectrolytes, SPARTHA Medical's products can be tailored to meet diverse requirements across various fields. These multifunctional and easy-to-apply coating solutions aim to help healthcare institutions maintain disease-free surfaces on medical devices, thereby enhancing patient safety and reducing infection risks.

Emergence Therapeutics AG is a biopharmaceutical company based in Duisburg, Germany, focused on developing novel antibody-drug conjugate (ADC) immuno-therapeutics for high-need cancers. Founded in 2019, the company is advancing its lead program, which combines a highly specific antibody with optimized linker and payload technology to target Nectin-4, a clinically validated target for various cancers. This approach is inspired by the success of enfortumab vedotin, an approved treatment for urothelial cancers. Emergence Therapeutics is also exploring opportunities to create additional first- or best-in-class ADCs, aiming to address significant therapeutic needs in oncology.

Perha Pharmaceuticals is a biotechnology company that specializes in the research and development of kinase inhibitors. The company's investigation begins with natural marine substances. Indeed, some of the molecules optimized by Perha Pharmaceuticals' chemists and biologists are derived from natural products isolated from marine organisms.

Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders . Their mission is to radically improve the health of patients suffering from incurable life threatening conditions. They do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

Egle Therapeutics SAS is a biotechnology company based in Paris, France, founded in 2020. It specializes in developing innovative immunotherapies that target immune suppressor regulatory T-cells (Tregs) for the treatment of oncology and autoimmune diseases. The company's research focuses on a proprietary drug pipeline that includes computationally designed IL-2 variants aimed at modulating Treg activity. This approach seeks to either engage or dis-engage Tregs, facilitating the development of therapies that can effectively combat cancer and other related conditions by addressing the immune suppression caused by Tregs. Egle Therapeutics aims to advance its unique portfolio to provide new treatment options in the healthcare field.

Agronutris is a biotechnology firm focused on rearing and transforming insects into proteins for animal nutrition and organic fertilizers. The company produces protein-rich products designed to meet the nutritional needs of various animals, particularly in the aquaculture and pet food sectors. Their offerings include insect meal with a high nutritional profile, as well as organic fertilizers like Fairtil, Ultrain, and Liboost. By leveraging bioconversion processes, Agronutris aims to contribute to sustainable practices within the agri-food industry, helping to address global food challenges while promoting environmental preservation.

TreeFrog Therapeutics is a developer of stem cells intended to secure cell production and quality, fasten clinical development and facilitate market access. The company's offerings include a proprietary technology platform that provides an end to end 3D scalable solution that will dramatically reduce treatment costs, enabling patients to access the medical revolution of cell therapies by overcoming current critical manufacturing issues.

Provepharm Life Solutions SA is a life sciences company based in Marseille, France, specializing in contract research and development services for small molecules and therapeutic peptides. Founded in 1998, the company focuses on the development, manufacturing, and marketing of pharmaceutical products and active ingredients. A key offering is pharmacopoeial grade methylene blue, a versatile compound utilized in various human health applications, including as an antidote for methemoglobinemia, a mild urinary antiseptic, and a topical antiseptic. The company also addresses animal health needs, providing solutions for toxicosis and aquaculture. Methylene blue serves additional roles as a laboratory dye, indicator, and diagnostic aid in surgical procedures. Provepharm Life Solutions aims to lead in the life sciences sector through its innovative approach, known as Molecule Vitalization, and offers a range of research and manufacturing services to advance health solutions.

PEP-Therapy is a biotechnology company focused on developing innovative peptide-based therapies aimed at treating severe diseases, particularly cancer. The company specializes in creating Cell Penetrating and Interfering Peptides (CP&IP), which are designed to penetrate cellular membranes and effectively block critical intracellular protein-protein interactions. By doing so, these peptides aim to inhibit essential pathological mechanisms, thereby offering targeted therapeutic options for healthcare providers. Through its research and development efforts, PEP-Therapy seeks to advance the field of targeted therapies and improve outcomes for patients facing serious health challenges.

Gourmey is a cultivated meat company based in Paris, France, founded in 2019. It specializes in producing ethical foie gras derived from duck cells, offering a sustainable alternative to traditional methods that involve force-feeding and slaughter. By cultivating animal cells in a controlled laboratory environment, Gourmey creates meat products that prioritize health, environmental sustainability, and animal welfare. The company aims to provide delicious meat options for consumers who are conscious of their choices and seek innovative solutions in the food industry.

Inotrem S.A. is a biotechnology company that specializes in immunotherapy aimed at managing acute and chronic inflammatory syndromes. The company focuses on the TREM-1 pathway to regulate excessive inflammatory responses, utilizing its proprietary technology platform. Inotrem has developed a first-in-class TREM-1 inhibitor known as nangibotide (LR12), which shows promise in treating conditions such as septic shock and myocardial infarction. In addition to its acute inflammatory initiatives, Inotrem is also advancing a program targeting chronic inflammatory diseases, thereby expanding its therapeutic scope. Through its innovative approach, Inotrem aims to enhance treatment options for critical care patients facing a variety of inflammatory challenges.

Gaiago is a powerful decision-making tool that uses soil analysis. For all crops and soil types, the firm offers a portfolio of successful synergistic products based on natural ingredients.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.

High value polysaccharides and pigments produced with high-output micro-algae and vertical photo-reactors.

Olgram is a biotechnology company that develops marine molecules for the prevention and control of chronic bacterial infections.Olgram has an original positioning to address this critical need by developing new products that will target, for the first time, dormant bacteria (responsible for infectious relapses) with a new class of anti-infectious.

Step Pharma, established in 2014 and based in Paris, France, focuses on developing innovative small molecule therapeutics for immunosuppressive therapies aimed at treating autoimmune diseases. As a spin-off from the Imagine Institute, the company leverages research on genetic immunodeficiencies conducted by Pr. Alain Fischer. Step Pharma operates as a joint venture with contributions from Imagine, Sygnature Discovery, and Kurma Partners, combining expertise in drug discovery and funding within the healthcare and biotechnology sectors. The company's proprietary therapeutics utilize a novel class of oral nucleotide synthesis inhibitors that specifically target cytidine triphosphate synthase 1 (CTPS1). This targeted approach enables selective modulation of immune cell populations, such as T and B cells, leading to enhanced treatment efficacy and improved therapeutic outcomes for patients with autoimmune conditions.

Seekyo is a privately-owned biotech company focused on developing advanced chemotherapies that specifically target the microenvironment of solid tumors. Its innovative approach aims to deliver potent anticancer agents while minimizing harm to healthy tissues, thereby reducing adverse effects for cancer patients. The company's "smart drugs" are designed to selectively transport these agents, utilizing a targeting unit for effective recognition of malignant cells. Additionally, Seekyo's technology incorporates a versatile enzyme-responsive self-immolative linker that enables controlled drug release exclusively at the tumor site. This targeted methodology seeks to enhance the efficacy and safety of cancer treatments, offering patients a more tolerable therapeutic option.

OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urotest (CE-IVD) is a urine test for diagnosis and surveillance of bladder cancer. The company's pipeline also includes the Colodiag in development for early detection of colorectal cancer.

Argobio is a start-up studio focused on developing innovative therapeutic solutions and fostering the growth of biotech firms. It collaborates with leading European academic research institutes to identify and nurture early-stage projects, particularly in the areas of rare diseases, neurological disorders, oncology, and immunology. By providing financial support and operational expertise, Argobio aims to cultivate these projects before launching them as independent companies. The studio also seeks to create promising platform technologies that can lead to new therapeutic products, thereby enhancing the drug research and development process for startups in the biotechnology sector.

Omini is a French company, established in 2019 and based in Saint Mandé, that specializes in the development of portable and multipurpose bio-sensing devices for blood testing. The company’s biosensor platform allows for the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to tailor therapies and prevent acute crises in patients with chronic conditions. By employing advanced multiplex electrochemical biosensor technology, Omini's devices offer accurate and affordable solutions for identifying, analyzing, and monitoring various target biomarkers. This innovation supports decentralized testing and at-home monitoring, ultimately aiming to alleviate the burden on healthcare systems and improve patient outcomes. Omini primarily serves general practitioners, enhancing their ability to manage patient care effectively.

Iktos is a French company focused on artificial intelligence and robotic solutions for medicinal chemistry and drug design. It offers a proprietary generative AI technology that optimizes molecule design for small molecule discovery projects, significantly enhancing productivity in pharmaceutical research and development. Iktos provides its innovative solutions through its SaaS platforms, Makya™ for generative drug design and Spaya™ for retrosynthesis, while also engaging in strategic partnerships with pharmaceutical companies to accelerate drug discovery. Additionally, Iktos has developed an AI-driven synthesis automation platform, Iktos Robotics, which expedites the Design-Make-Test-Analyze cycle in drug development. The company is also advancing its own pipeline of drug candidates aimed at oncology and autoimmune diseases. In March 2023, Iktos secured a significant financing round, and in July 2024, it enhanced its capabilities by acquiring Synsight, which adds a biology platform for discovering drugs targeting Protein-Protein and RNA-Protein interactions.

NovAliX is a research organization specializing in drug discovery and pharmaceutical development. It provides a range of integrated services designed to address the outsourcing needs of the pharmaceutical industry, from initial discovery through to manufacturing. Utilizing proprietary technologies such as surface plasmon resonance (SPR), X-ray protein crystallography, and advanced NMR techniques, NovAliX offers comprehensive support for small molecule drug discovery and biologics characterization. The company's collaborative approach enables clients to access a unique combination of screening, medicinal chemistry, and structural biology, facilitating the development of effective drugs. Additionally, NovAliX conducts thorough analyses of active pharmaceutical ingredients (APIs) and polymorphism studies, supporting pharmaceutical development and manufacturing teams in their efforts to bring new therapies to market.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes, France, specializing in the development of innovative immunotherapies aimed at immune activation and regulation, particularly in the areas of immuno-oncology and autoimmune diseases. The company's product portfolio includes Tedopi, which is in Phase III clinical trials for lung cancer and Phase II for pancreatic cancer; BI 765063, currently in Phase I trials for solid tumors; and OSE-703, a humanized monoclonal antibody in preclinical development for various cancers. Additionally, OSE Immunotherapeutics is advancing FR104, which is in Phase I trials for rheumatoid arthritis, and OSE-127, a humanized monoclonal antibody in Phase I trials for inflammatory autoimmune diseases. The company collaborates with notable partners such as GERCOR, Memorial Sloan Kettering Cancer Center, Boehringer Ingelheim, Servier, and HalioDx. OSE Immunotherapeutics was previously known as OSE Pharma SA before its name change in May 2016.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

ERYtech Pharma specializes in the encapsulation of therapeutic molecules and enzymes in red blood cells. It has achieved a major breakthrough in the fields of cancer and enzyme therapy by significantly increasing the therapeutic index of the encapsulated molecule or enzyme.

SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly 2 million people worldwide.

TISSIUM is a privately owned medical device company based in Paris, France, focused on developing and commercializing innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, bind effectively to tissues, and provide on-demand wound closure in the body’s dynamic environments. TISSIUM's technology is rooted in advanced research and intellectual property from renowned experts at MIT and Brigham & Women’s Hospital. The company aims to address various unmet clinical needs through its proprietary portfolio of fully biosynthetic, biomorphic, and programmable polymers. Founded in 2013, TISSIUM is supported by prominent healthcare investors, emphasizing its commitment to advancing surgical techniques through its groundbreaking solutions.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative retinal implant systems to restore vision for individuals who have lost sight due to degeneration of photoreceptor cells in the retina. Established in 2011, Pixium Vision's primary product is the PRIMA System, a bionic vision system designed to improve visual perception and promote greater independence among users. The company is advancing several devices, including the IRIS1, currently undergoing clinical trials, and the next-generation IRIS2, which aims to enhance visual acuity. Additionally, Pixium is working on the IRIS3, a sub-retinal implant that promises further improvements in vision. The company collaborates with prestigious institutions such as Stanford University, Moorfields Eye Hospital, and the Institut de la Vision, utilizing cutting-edge research in neural processing and micro-electronics to drive its innovations. Pixium Vision is supported by a consortium of prominent European venture capital firms.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

Honing Biosciences SAS is a bio-therapeutics company based in Paris, France, specializing in the development and enhancement of cell-based therapies for cancer and other chronic diseases. The company utilizes its proprietary molecular CellTune technology to create tunable cell therapeutics that enable precise control over the dynamic delivery of proteins in patients. This innovation allows for the regulation of protein expression at the cell surface and the secretion of therapeutic agents such as enzymes, cytokines, and antibodies, which can be adapted based on the clinical progression of a patient's condition. Honing Biosciences also offers therapies like CAR-T cell therapy and checkpoint inhibitors, which aim to improve treatment efficacy while minimizing adverse effects associated with earlier therapeutic generations. Established in 2018, the company focuses on advancing immunotherapy and reconstituting cell therapies to better engage the body’s immune system in combating diseases.